Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2322677 | 0.92 | CA1 (0.33) | TSHRCA1CA2 | |
| SCHEMBL2322189 | 0.90 | THRB (0.38) | TSHRCA1CA2 | |
| SCHEMBL4266555 | 0.90 | THRB (0.38) | TSHRCA1CA2 | |
| SCHEMBL2343297 | 0.90 | ADRB2 (0.35) | ADRB2ADRB1ADRB3TSHRCYP3A4 | |
| SCHEMBL2325605 | 0.90 | THRB (0.38) | TSHRCA1CA2 | |
| SCHEMBL2329171 | 0.90 | ADRB2 (0.32) | ADRB2ADRB1ADRB3TSHRLMNA | |
| SCHEMBL2344113 | 0.83 | CA1 (0.31) | TSHRCA1CA2 | |
| SCHEMBL2344571 | 0.81 | THRB (0.35) | TSHRCA1CA2 | |
| SCHEMBL2341006 | 0.81 | THRB (0.35) | TSHRCA1CA2 | |
| SCHEMBL2344612 | 0.81 | THRB (0.35) | TSHRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1760085-B1 | PROCESS FOR PRODUCTION OF ALKYLTIN ALKOXIDES | ASAHI KASEI CHEMICALS CORP (JP) | 2014-02-26 | — | — | EP | disclosed |
| EP-1987881-B1 | METHOD FOR SEPARATION AND COLLECTION OF DIALKYL TIN DIALKOXIDE | ASAHI KASEI CHEMICALS CORP (JP) | 2011-08-17 | — | — | EP | disclosed |
| US-7842828-B2 | Method for separating out and recovering dialkyltin dialkoxide | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2010-11-30 | — | — | US | disclosed |
| US-20100160662-A1 | Method for Separating Out and Recovering Dialkyltin Dialkoxide | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2010-06-24 | — | — | US | disclosed |
| US-7541482-B2 | Process for production of alkyltin alkoxides | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20080275262-A1 | Process for Production of Alkyltin Alkoxides | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2008-11-06 | — | — | US | disclosed |
| EP-1987881-A1 | METHOD FOR SEPARATION AND COLLECTION OF DIALKYL TIN DIALKOXIDE | Asahi Kasei Chemicals Corporation (JP) | 2008-11-05 | — | — | EP | disclosed |
| EP-1760085-A1 | PROCESS FOR PRODUCTION OF ALKYLTIN ALKOXIDES | Asahi Kasei Chemicals Corporation (JP) | 2007-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160662-A1 | Method for Separating Out and Recovering Dialkyltin Dialkoxide | ALOX5, ALOX15B, ALOX15 | ADRB2 2528/4885ADRB1 2689/4885ADRB3 3759/4885 |
| US-20080275262-A1 | Process for Production of Alkyltin Alkoxides | ALK, MOGAT2, SOAT2 | ADRB2 4080/4885ADRB1 3943/4885ADRB3 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.